Twist Bioscience Corporation and Ildong Pharmaceutical announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology. Under the terms of the agreement, Ildong will license a suite of Twist's VHH libraries for a period of three years and will use the libraries to conduct research and development activities. Twist will receive an upfront payment, annual maintenance fees and additional payments for success-based clinical and regulatory milestones as well as royalties on product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.37 USD | -1.92% | +2.81% | +14.95% |
03/05 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
03/05 | Sector Update: Health Care Stocks Mixed in Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.95% | 2.47B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation and Ildong Pharmaceutical Enter into Collaboration to Enhance Antibody Discovery for Applications in Immuno-Oncology